Nátrium-Klorid Aptapharma (Sodium Chloride)

The product delivers sodium (Na+) and chloride (Cl‑) ions directly into the bloodstream. These ions increase extracellular osmolarity, drawing water from cells into the vascular compartment, which expands intravascular volume and corrects deficits in sodium and chloride, supporting normal fluid distribution and hemodynamic stability.

The dose of Nátrium-Klorid Aptapharma is determined by the prescribing clinician based on the patient’s fluid loss, electrolyte status, and clinical condition. The healthcare professional selects the appropriate concentration, volume, and infusion rate to safely achieve the desired therapeutic effect.

Safety data for sodium chloride injection in pregnancy and lactation are limited. It should only be used when clearly needed and prescribed by a qualified healthcare provider who can weigh the potential benefits against any possible risks to the mother and fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nátrium-Klorid Aptapharma provides a pure sodium chloride formulation, offering precise control of Na+ and Cl‑ delivery. Compared with balanced electrolyte solutions that contain additional ions (e.g., potassium, calcium), it is useful when only sodium and chloride replacement is required, but may need supplementation if other electrolytes are deficient.

The product should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if necessary, and inspect for particulate matter or discoloration.

It is administered intravenously by slow infusion through a suitable IV line. The infusion rate is set by the prescribing clinician, often based on the patient’s hemodynamic status and the volume needed to correct fluid deficits. Monitoring during administration is recommended.

Serious risks include severe hypernatremia, hyperchloremic metabolic acidosis, pulmonary edema, and rare anaphylactic reactions. These events are more likely if the infusion is given too rapidly, in excessive volumes, or to patients with pre‑existing electrolyte disturbances or cardiac/renal impairment.

Patients with existing severe hypernatremia, marked fluid overload, or uncontrolled heart failure should avoid this product unless under strict medical supervision. Additionally, individuals with known hypersensitivity to sodium chloride solutions should not receive it.